Allen Kaplan to Young Adult
This is a "connection" page, showing publications Allen Kaplan has written about Young Adult.
Connection Strength
0.167
-
Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study. J Am Acad Dermatol. 2018 04; 78(4):793-795.
Score: 0.066
-
Omalizumab is effective in nonautoimmune urticaria. J Allergy Clin Immunol. 2011 May; 127(5):1300-2.
Score: 0.041
-
Analysis of cold activation of the contact system in hereditary angioedema with normal C1 inhibitor. Mol Immunol. 2021 08; 136:150-160.
Score: 0.021
-
Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2017 Oct; 31(10):1715-1721.
Score: 0.016
-
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013 Mar 07; 368(10):924-35.
Score: 0.012
-
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011 Sep; 128(3):567-73.e1.
Score: 0.011